About FDA

David L. Ashley, Ph.D., and Matthew R. Holman, Ph.D., Directors, Office of Science

David L. Ashley, PhD, Director, Office of Science

David L. Ashley, Ph.D., Director, Office of Science

David L. Ashley, Ph.D. is currently Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration.  He was appointed to that position in June 2010. The Office of Science at CTP is responsible for identifying, developing, and enhancing the science related to tobacco products, their use, and the resulting morbidity and mortality so that regulatory decisions will have the greatest impact on improving public health. To accomplish this goal they provide the scientific support for regulations and guidance, review tobacco product applications, evaluate the knowledge basis for regulatory decisions, and carry out research to fill the gaps in scientific knowledge related to tobacco product regulation. He received his Ph.D. in Physical Chemistry from Emory University in Atlanta, Georgia in 1982. 
 
Before taking on his current position at FDA, Dr. Ashley worked at the U.S. Centers for Disease Control and Prevention starting in 1983. At CDC, Dr. Ashley directed a branch of 87 scientists with a diverse public health mission including biomarkers of heavy metals, measurement of biomarkers of volatile organic compounds, biomarkers of tobacco use, and analysis of chemical constituents of tobacco products.  He has performed extensive research related to the impact of cigarette design and contents on the emissions from tobacco products, how people use the product and resulting biomarkers of exposure.  He has published over 140 peer-reviewed articles and book chapters related to biophysics, environmental chemicals, biomarkers of exposure and the constituents of tobacco and tobacco smoke.  He was a contributing author for the recent Surgeon General's Report entitled How Tobacco Causes Disease--The Biology and Behavioral Basis for Tobacco-Attributable Disease. He has presented extensively at scientific meetings on the chemistry of tobacco and tobacco smoke and biomarkers of exposure. Dr. Ashley serves on the World Health Organization (WHO) Study Group for Tobacco Product Regulation and was the Chair of the WHO Tobacco Laboratory Network from 2006 until 2010.


Matthew R. Holman, Ph.D., Director, Office of Science

Matthew R. Holman, Ph.D., Director, Office of Science

Matthew R. Holman, Ph.D. is currently Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration (FDA). He was appointed to that position in January 2017. The Office of Science at CTP is responsible for identifying, developing, and enhancing the science related to tobacco products, their use, and the resulting morbidity and mortality so that regulatory decisions will have the greatest impact on improving public health. To accomplish this goal, they provide the scientific support for regulations and guidance, review tobacco product applications, evaluate the knowledge basis for regulatory decisions, and carry out research to fill the gaps in scientific knowledge related to tobacco product regulation. He received his Ph.D. in Biochemistry from the University of Maryland at College Park in 2000.

Before taking on his current position, Dr. Holman served as Director of the Division of Product Science within CTP’s Office of Science for six years. In this position, he oversaw evaluation of the composition and design of tobacco products. In addition, he was involved in chemical, microbiological, and engineering research on tobacco products, resulting in numerous publications in peer-reviewed scientific journals. During this time, Dr. Holman also served as Technical Project Lead (TPL) in reviewing over a thousand SE Reports. As TPL, he was responsible for the overall scientific review of SE Reports by CTP. Before his tenure at CTP, he worked in FDA’s Center for Drug Evaluation and Research (CDER) on over-the-counter drug products. He served in a few positions within CDER, with his last position being Deputy Director of the Division of Nonprescription Regulation Development. In this role, he was involved in the publication of approximately 50 rulemakings, guidance documents, and other Federal Register notices.

Page Last Updated: 01/30/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English